Atlas Venture Closes Fund XII at $400 Million, Promotes Gladstone to Partner

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Matchpoint Gets $100M to Take Covalent Binders Into Autoimmune Disease
Atlas, Medicxi Invest $70M in Antibody for Obesity Licensed from Novartis
SpringWorks Faces Readout for Gamma Secretase Inhibitor; Eyes BCMA Combo for Cancer
Versant Ventures Wagers $35M on Cytokine Engineering with Bright Peak